Spotlight on Internal Medicine

Credits: 1.00 CME / CNE / CPE
Navigating the Complexity of Pulmonary Arterial Hypertension: Advances in the Diagnosis and Management – Part III: Latest Data on PAH Treatment Approaches
Vallerie V. McLaughlin, MD
The Postgraduate Institute for Medicine

Navigating the Complexity of Pulmonary Arterial Hypertension: Advances in the Diagnosis and Management – Part III: Latest Data on PAH Treatment Approaches

Start

Activity Details

Free CME/CNE/CPE
1 AMA PRA Category 1 Credit(s)
1 contact hour(s)
Released: June 17, 2021
Expires: June 17, 2022
60 minutes to complete

Accredited By

Target Audience

The activity will target a global audience of cardiologists, lipidologists, primary care physicians, nurses, physician assistants, and pharmacists.

Learning Objectives

  • Evaluate the potential role of cardiac MRI metrics and other cardiac endpoints in PAH risk stratification
  • Interpret the results of recent trials for transition of PAH therapies
  • Summarize real-world data from PAH registries and their potential implications for management

Faculty

Vallerie V. McLaughlin, MD
Professor of Cardiovascular Medicine
Director of the Pulmonary Hypertension Program
University of Michigan
Ann Arbor, MI

Dr. McLaughlin discloses the following:
Consulting Fees: Acceleron, Actelion, Altavant, Caremark, Civi Biopharma, Gossamer, Liquida, United Therapeutics
Contracted Research: Acceleron, Actelion, Gilead, Sonivie, Reata, United Therapeutics

Stephan Rosenkranz, MD
Professor
Department of Cardiology, Pulmonology, and Intensive Care Medicine
Center for Molecular Medicine Cologne (CMMC)
Cologne Cardiovascular Research Center (CCRC)
Heart Center at the University of Cologne
Cologne, Germany

Dr. Rosenkranz discloses the following:
Consulting Fees and Fees for Non-CME Services Received Directly from a Commercial Interest: Abbott, Acceleron, Actelion, Bayer, BMS, MSD, Novartis, Pfizer, Ferrer, United Therapeutics, Vifor
Contracted Research to Institution: Actelion, AstraZeneca, Bayer, Novartis, Pfizer, Janssen

Conflict of Interest Policy/Disclosure Statement

Postgraduate Institute for Medicine (PIM) requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose any real or apparent conflict of interest (COI) they may have as related to the content of this activity. All identified COI are thoroughly vetted and resolved according to PIM policy. PIM is committed to providing its learners with high quality activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of a commercial interest.

Planners and Managers
The PIM planners and managers have nothing to disclose.
The CMHC planners and managers have nothing to disclose.

Joint Accreditation Statement

In support of improving patient care, this activity has been planned and implemented by the Postgraduate Institute for Medicine and Tarsus Cardio Inc. dba Cardiometabolic Health Congress (CMHC). Postgraduate Institute for Medicine is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

PHYSICIAN CONTINUING MEDICAL EDUCATION
The Postgraduate Institute for Medicine designates this enduring material for a maximum of 1 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credits commensurate with the extent of their participation in the activity.

CONTINUING NURSING EDUCATION
The maximum number of hours awarded for this Continuing Nursing Education activity is 1 contact hour(s). Pharmacotherapy contact hours for Advanced Practice Registered Nurses will be designated on your certificate.

CONTINUING PHARMACY EDUCATION
Postgraduate Institute for Medicine designates this continuing education activity for 1 contact hour(s) (0.1 CEUs) of the Accreditation Council for Pharmacy Education.

This is a knowledge-based activity. Universal Activity Numbers (UAN): # JA4008162-9999-21-2781-H01-P

For Pharmacists: Upon completing the post-test and the activity evaluation form, transcript information will be sent to the NABP CPE Monitor Service within 4 – 6 weeks.

Statement of Commercial Support

Supported by an educational grant from Merck Sharp & Dohme Corp.

Disclaimer Statement/Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications. The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Contact Information for Questions About the Activity

For questions about the accreditation of this activity, please visit www.pimed.com.

Activity Details

Free CME/CNE/CPE
1 AMA PRA Category 1 Credit(s)
1 contact hour(s)
Released: June 17, 2021
Expires: June 17, 2022
60 minutes to complete

Accredited By

Target Audience

The activity will target a global audience of cardiologists, lipidologists, primary care physicians, nurses, physician assistants, and pharmacists.

Learning Objectives

  • Evaluate the potential role of cardiac MRI metrics and other cardiac endpoints in PAH risk stratification
  • Interpret the results of recent trials for transition of PAH therapies
  • Summarize real-world data from PAH registries and their potential implications for management

Faculty

Vallerie V. McLaughlin, MD
Professor of Cardiovascular Medicine
Director of the Pulmonary Hypertension Program
University of Michigan
Ann Arbor, MI

Dr. McLaughlin discloses the following:
Consulting Fees: Acceleron, Actelion, Altavant, Caremark, Civi Biopharma, Gossamer, Liquida, United Therapeutics
Contracted Research: Acceleron, Actelion, Gilead, Sonivie, Reata, United Therapeutics

Stephan Rosenkranz, MD
Professor
Department of Cardiology, Pulmonology, and Intensive Care Medicine
Center for Molecular Medicine Cologne (CMMC)
Cologne Cardiovascular Research Center (CCRC)
Heart Center at the University of Cologne
Cologne, Germany

Dr. Rosenkranz discloses the following:
Consulting Fees and Fees for Non-CME Services Received Directly from a Commercial Interest: Abbott, Acceleron, Actelion, Bayer, BMS, MSD, Novartis, Pfizer, Ferrer, United Therapeutics, Vifor
Contracted Research to Institution: Actelion, AstraZeneca, Bayer, Novartis, Pfizer, Janssen

Conflict of Interest Policy/Disclosure Statement

Postgraduate Institute for Medicine (PIM) requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose any real or apparent conflict of interest (COI) they may have as related to the content of this activity. All identified COI are thoroughly vetted and resolved according to PIM policy. PIM is committed to providing its learners with high quality activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of a commercial interest.

Planners and Managers
The PIM planners and managers have nothing to disclose.
The CMHC planners and managers have nothing to disclose.

Joint Accreditation Statement

In support of improving patient care, this activity has been planned and implemented by the Postgraduate Institute for Medicine and Tarsus Cardio Inc. dba Cardiometabolic Health Congress (CMHC). Postgraduate Institute for Medicine is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

PHYSICIAN CONTINUING MEDICAL EDUCATION
The Postgraduate Institute for Medicine designates this enduring material for a maximum of 1 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credits commensurate with the extent of their participation in the activity.

CONTINUING NURSING EDUCATION
The maximum number of hours awarded for this Continuing Nursing Education activity is 1 contact hour(s). Pharmacotherapy contact hours for Advanced Practice Registered Nurses will be designated on your certificate.

CONTINUING PHARMACY EDUCATION
Postgraduate Institute for Medicine designates this continuing education activity for 1 contact hour(s) (0.1 CEUs) of the Accreditation Council for Pharmacy Education.

This is a knowledge-based activity. Universal Activity Numbers (UAN): # JA4008162-9999-21-2781-H01-P

For Pharmacists: Upon completing the post-test and the activity evaluation form, transcript information will be sent to the NABP CPE Monitor Service within 4 – 6 weeks.

Statement of Commercial Support

Supported by an educational grant from Merck Sharp & Dohme Corp.

Disclaimer Statement/Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications. The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Contact Information for Questions About the Activity

For questions about the accreditation of this activity, please visit www.pimed.com.

Internal Medicine Presentations

1.00 CME / MOC / CNE
American Heart Association
W.O.W. Why HOw and When to measure Lipoprotein(a): A Clinically Relevant Cardiovascular Risk Factor

W.O.W. Why HOw and When to measure Lipoprotein(a): A Clinically Relevant Cardiovascular Risk Factor

Start

Activity Details

Free CME/MOC/CNE
1.0 AMA PRA Category 1 Credit(s)
1.0 ABIM MOC credit(s)
1.0 Contact Hour(s)
Released: September 13, 2021
Expires: September 12, 2022
60 minutes to complete

Accredited By

Target Audience

Includes but is not limited to cardiologists, interventional cardiologists, preventative cardiologists, LDL specialists, nurse practitioners, physician assistants, nurses, etc.

Learning Objectives

  1. Define Lipoprotein(a)
  2. Describe WHY Lipoprotein(a) should be measured
  3. Explain HOW to measure Lipoprotein(a)
  4. Indicate WHEN to measure Lipoprotein(a)

Activity Description

This webinar will cover the principles of why, how and when clinicians should consider measuring Lipoprotein(a) levels. It will be based on the latest available scientific evidence and support the ongoing guidelines/methods being used in the field.

Statement of Educational Need

  • Clinicians lack knowledge about why they should measure Lipoprotein(a)
  • Clinicians do not know how to measure Lipoprotein(a)
  • Clinicians do not recognize when to measure Lipoprotein(a)

Faculty

Bart Duell, MD
Professor of Medicine
Division of Cardiovascular Medicine, School of Medicine
Oregon Science & Health University
Portland, Oregon

Disclosure: Akcea


Gissette Reyes-Soffer, MD
Herbert Irving Assistant Professor of Medicine
Columbia University Medical Center
College of Physicians and Surgeons
New York, New York

Disclosure: Amgen, Inc.


Pia Kamstrup, MD, PhD
Head of Department of Clinical Biochemistry
Herlev and Gentofte Hospital
Copenhagen University Hospital
Copenhagen, Denmark

Disclosure: None reported relevant to this webinar.


Calvin Yeang, MD, PhD
Cardiologist
UC San Diego Health
San Diego, California

Disclosure: Kaneka, Ionis Pharmaceuticals

Conflict of Interest Policy/Disclosure Statement

All persons who develop and/or control educational content in CME/CE activities provided by the American Heart Association will disclose to the audience all financial relationships with any commercial supporters of this activity as well as with other commercial interests whose lines of business are related to the CME/CE-certified content of this activity. In addition, presenters will disclose unlabeled/unapproved uses of drugs or devices discussed in their presentations. Such disclosures will be made in writing in course presentation materials.

Joint Accreditation Statement

Accreditation Council for Pharmacy EducationIn support of improving patient care, this activity has been planned and implemented by the American Heart Association. The American Heart Association is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team.

AMA Credit Designation Statement – Physicians
The American Heart Association designates this enduring activity for a maximum of 1.0 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

MOC Statement
Successful completion of this CE activity, which includes participation in the evaluation component, enables the participant to earn up to 1.0 MOC points in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CE credits claimed for the activity. It is the CE activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

AAPA Credit Acceptance Statement – Physician Assistants
AAPA accepts certificates of participation for educational activities certified for AMA PRA Category 1 Credit(s)™ from organizations accredited by ACCME or a recognized state medical society. Physician assistants may receive a maximum of 1.0 hour of Category I credit for completing this program.

AANP Credit Acceptance Statement – Nurse Practitioners
American Academy of Nurse Practitioners (AANP) accepts AMA PRA Category 1 Credit(s)™ from organizations accredited by the ACCME.

ANCC Credit Designation Statement – Nurses
The maximum number of hours awarded for this CE activity is 1.0 contact hours.

Statement of Commercial Support

This activity is supported by an educational grant from Kaneka Corporation.

Disclaimer Statement/Disclosure of Unlabeled Use

When an unlabeled use of a commercial product or an investigational use not yet approved for any purpose is discussed during an educational activity, the faculty must disclose that the product is not labeled for the use under discussion or that the product is still investigational.

Contact Information for Questions About the Activity

Please contact Sheila Jackson at the American Heart Association at Sheila.Jackson@heart.org with any questions.

Activity Details

Free CME/MOC/CNE
1.0 AMA PRA Category 1 Credit(s)
1.0 ABIM MOC credit(s)
1.0 Contact Hour(s)
Released: September 13, 2021
Expires: September 12, 2022
60 minutes to complete

Accredited By

Target Audience

Includes but is not limited to cardiologists, interventional cardiologists, preventative cardiologists, LDL specialists, nurse practitioners, physician assistants, nurses, etc.

Learning Objectives

  1. Define Lipoprotein(a)
  2. Describe WHY Lipoprotein(a) should be measured
  3. Explain HOW to measure Lipoprotein(a)
  4. Indicate WHEN to measure Lipoprotein(a)

Activity Description

This webinar will cover the principles of why, how and when clinicians should consider measuring Lipoprotein(a) levels. It will be based on the latest available scientific evidence and support the ongoing guidelines/methods being used in the field.

Statement of Educational Need

  • Clinicians lack knowledge about why they should measure Lipoprotein(a)
  • Clinicians do not know how to measure Lipoprotein(a)
  • Clinicians do not recognize when to measure Lipoprotein(a)

Faculty

Bart Duell, MD
Professor of Medicine
Division of Cardiovascular Medicine, School of Medicine
Oregon Science & Health University
Portland, Oregon

Disclosure: Akcea


Gissette Reyes-Soffer, MD
Herbert Irving Assistant Professor of Medicine
Columbia University Medical Center
College of Physicians and Surgeons
New York, New York

Disclosure: Amgen, Inc.


Pia Kamstrup, MD, PhD
Head of Department of Clinical Biochemistry
Herlev and Gentofte Hospital
Copenhagen University Hospital
Copenhagen, Denmark

Disclosure: None reported relevant to this webinar.


Calvin Yeang, MD, PhD
Cardiologist
UC San Diego Health
San Diego, California

Disclosure: Kaneka, Ionis Pharmaceuticals

Conflict of Interest Policy/Disclosure Statement

All persons who develop and/or control educational content in CME/CE activities provided by the American Heart Association will disclose to the audience all financial relationships with any commercial supporters of this activity as well as with other commercial interests whose lines of business are related to the CME/CE-certified content of this activity. In addition, presenters will disclose unlabeled/unapproved uses of drugs or devices discussed in their presentations. Such disclosures will be made in writing in course presentation materials.

Joint Accreditation Statement

Accreditation Council for Pharmacy EducationIn support of improving patient care, this activity has been planned and implemented by the American Heart Association. The American Heart Association is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team.

AMA Credit Designation Statement – Physicians
The American Heart Association designates this enduring activity for a maximum of 1.0 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

MOC Statement
Successful completion of this CE activity, which includes participation in the evaluation component, enables the participant to earn up to 1.0 MOC points in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CE credits claimed for the activity. It is the CE activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

AAPA Credit Acceptance Statement – Physician Assistants
AAPA accepts certificates of participation for educational activities certified for AMA PRA Category 1 Credit(s)™ from organizations accredited by ACCME or a recognized state medical society. Physician assistants may receive a maximum of 1.0 hour of Category I credit for completing this program.

AANP Credit Acceptance Statement – Nurse Practitioners
American Academy of Nurse Practitioners (AANP) accepts AMA PRA Category 1 Credit(s)™ from organizations accredited by the ACCME.

ANCC Credit Designation Statement – Nurses
The maximum number of hours awarded for this CE activity is 1.0 contact hours.

Statement of Commercial Support

This activity is supported by an educational grant from Kaneka Corporation.

Disclaimer Statement/Disclosure of Unlabeled Use

When an unlabeled use of a commercial product or an investigational use not yet approved for any purpose is discussed during an educational activity, the faculty must disclose that the product is not labeled for the use under discussion or that the product is still investigational.

Contact Information for Questions About the Activity

Please contact Sheila Jackson at the American Heart Association at Sheila.Jackson@heart.org with any questions.

0.50 CME / MOC
RMEI Medical Education, LLC
Overcoming Hurdles to Optimal Care for Patients with NTM-LD

Overcoming Hurdles to Optimal Care for Patients with NTM-LD

Start

Activity Details

Free CME/MOC
0.5 AMA PRA Category 1 Credit(s)
0.5 ABIM MOC Point(s)
Released: August 17, 2021
Expires: August 16, 2022
30 minutes to complete

Provided By

Provided by RMEI Medical Education, LLC.

Target Audience

This activity is intended for pulmonology, infectious disease, internal medicine clinicians, and other healthcare professionals involved in the treatment of patients with nontuberculous mycobacterial lung disease (NTM-LD).

Learning Objectives

Upon completion of this activity, participants should be better able to:

  • Employ current data, guidelines, and best practices when managing individuals with nontuberculous mycobacterial lung disease (NTM-LD)
  • Apply strategies to maintain adherence and address treatment-related adverse effects in patients with NTM-LD

Activity Description

In this activity, a panel of experts discuss current guidelines and best practices for the management of nontuberculous mycobacterial lung disease (NTM-LD), including treatment options for refractory disease and strategies for minimizing adverse effects of therapies. An experienced patient with NTM-LD shares her experiences with oral and inhaled therapies and how she overcame treatment challenges.

Chair

Patrick A. Flume, MD
Professor, Medicine and Pediatrics
Medical University of South Carolina
Charleston, SC

Faculty

Doreen J. Addrizzo-Harris, MD
Professor of Medicine
Associate Director, Clinical and Academic Affairs
Director, NYU Bronchiectasis/NTM Program
NYU Grossman School of Medicine
New York, NY


Julie V. Philley, MD
Executive Vice President, Health Affairs
University of Texas Health Science Center at Tyler
Tyler, TX

Disclosure of Financial Relationships

RMEI Medical Education, LLC (RMEI) requires instructors, planners, managers, and others in control of educational content to disclose all their financial relationships with ineligible companies over the previous 24 months. All identified financial relationships are thoroughly vetted and mitigated according to RMEI policy. RMEI is committed to providing its learners with high quality accredited continuing education activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company.

The faculty reported the following relevant financial relationships with ineligible entities related to the educational content of this CE activity:

Faculty
Patrick A. Flume, MD, has financial relationships with AbbVie, Armata, AstraZeneca, Corbus Pharmaceuticals, Cystic Fibrosis Foundation Therapeutics, Insmed, Janssen, Merck, National Institutes of Health, Novartis, Novoteris, Novovax, Proteostasis Therapeutics, Savara, Sound Pharmaceuticals, Inc., Vertex Pharmaceuticals, Inc. (Grant/Research Support); Arrevus, Chiesi, Corbus Pharmaceuticals, Eloxx Pharmaceuticals, Hill-Rom, Insmed, Ionis Pharmaceuticals, Janssen Research & Development, McKesson, Merck, Novartis, Polyphor, Proteostasis Therapeutics, Santhera, Savara, Vertex Pharmaceuticals, Inc. (Consultant).

Doreen J. Addrizzo-Harris, MD, has no financial relationships to disclose.

Julie V. Philley, MD, has financial relationships with Insmed (Speaker's Bureau); A2N, Electromed, Insmed, Paratek (Consultant); A2N, Electromed, Hillrom, Insmed, Paratek, RedHill, Zambon (Grant/Research Support).

Patient
Patient participating in this activity has no relevant financial relationship(s) with ineligible companies to disclose.

Planners and Managers
RMEI Medical Education, LLC planners and managers have no relevant financial relationship(s) with ineligible companies to disclose.

All of the relevant financial relationships listed for these individuals have been mitigated according to RMEI policies.

Accreditation Statement

In support of improving patient care, RMEI Medical Education, LLC is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Physician Continuing Medical Education
RMEI Medical Education, LLC designates this enduring material for a maximum of 0.5 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

American Board of Internal Medicine Maintenance of Certification
Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 0.5 medical knowledge MOC point(s) in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

Criteria for Success

In order to receive credit, participants must review the activity content and successfully complete both the post-test and evaluation. A statement of credit will be available to print immediately. You must score 75% or higher on the post-test to receive credit for this activity. If you have questions about this activity, please contact RMEI at contact@rmei.com.

Users must:

  • Read the learning objectives and faculty disclosures
  • Participate in the activity
  • Complete the activity evaluation and attest to credit

In order to claim MOC point(s), users must:

  • Provide ABIM ID and month/date of birth and score 75% or higher on the post-test

MOC points will be submitted to ABIM profiles within 4 weeks of completion.

There is no fee for this educational activity.

Your Feedback is Important!

COMPLETE THE EVALUATION FORM AND YOU WILL BE ENTERED
INTO A DRAWING FOR A $100* AMAZON GIFT CARD!

*The expense for this gift card is solely funded by RMEI Medical Education, LLC.
No supporter funding was used for the expense of this gift card.

Rules and Regulations 
This sweepstakes is managed by RMEI Medical Education, LLC (RMEI), a jointly accredited provider. The winner will be selected via automated random drawing on a quarterly basis from among all eligible entries and notified through the contact information provided. In accordance with our privacy policy, we do not share your information with any third parties. By entering the sweepstakes, you grant RMEI permission to use your e-mail address to reach you for notification and prize fulfillment. Only individuals who complete the evaluation forms and provide contact information will be eligible to win. Open to those who have a US postal address and who are 18 years or older. Only one prize per person and per household will be awarded. The prize will be a $100 Amazon gift card.

Statement of Commercial Support

This activity is supported by an educational grant from Insmed.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications. The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient's conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer's product information, and comparison with recommendations of other authorities.

Activity Details

Free CME/MOC
0.5 AMA PRA Category 1 Credit(s)
0.5 ABIM MOC Point(s)
Released: August 17, 2021
Expires: August 16, 2022
30 minutes to complete

Provided By

Provided by RMEI Medical Education, LLC.

Target Audience

This activity is intended for pulmonology, infectious disease, internal medicine clinicians, and other healthcare professionals involved in the treatment of patients with nontuberculous mycobacterial lung disease (NTM-LD).

Learning Objectives

Upon completion of this activity, participants should be better able to:

  • Employ current data, guidelines, and best practices when managing individuals with nontuberculous mycobacterial lung disease (NTM-LD)
  • Apply strategies to maintain adherence and address treatment-related adverse effects in patients with NTM-LD

Activity Description

In this activity, a panel of experts discuss current guidelines and best practices for the management of nontuberculous mycobacterial lung disease (NTM-LD), including treatment options for refractory disease and strategies for minimizing adverse effects of therapies. An experienced patient with NTM-LD shares her experiences with oral and inhaled therapies and how she overcame treatment challenges.

Chair

Patrick A. Flume, MD
Professor, Medicine and Pediatrics
Medical University of South Carolina
Charleston, SC

Faculty

Doreen J. Addrizzo-Harris, MD
Professor of Medicine
Associate Director, Clinical and Academic Affairs
Director, NYU Bronchiectasis/NTM Program
NYU Grossman School of Medicine
New York, NY


Julie V. Philley, MD
Executive Vice President, Health Affairs
University of Texas Health Science Center at Tyler
Tyler, TX

Disclosure of Financial Relationships

RMEI Medical Education, LLC (RMEI) requires instructors, planners, managers, and others in control of educational content to disclose all their financial relationships with ineligible companies over the previous 24 months. All identified financial relationships are thoroughly vetted and mitigated according to RMEI policy. RMEI is committed to providing its learners with high quality accredited continuing education activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company.

The faculty reported the following relevant financial relationships with ineligible entities related to the educational content of this CE activity:

Faculty
Patrick A. Flume, MD, has financial relationships with AbbVie, Armata, AstraZeneca, Corbus Pharmaceuticals, Cystic Fibrosis Foundation Therapeutics, Insmed, Janssen, Merck, National Institutes of Health, Novartis, Novoteris, Novovax, Proteostasis Therapeutics, Savara, Sound Pharmaceuticals, Inc., Vertex Pharmaceuticals, Inc. (Grant/Research Support); Arrevus, Chiesi, Corbus Pharmaceuticals, Eloxx Pharmaceuticals, Hill-Rom, Insmed, Ionis Pharmaceuticals, Janssen Research & Development, McKesson, Merck, Novartis, Polyphor, Proteostasis Therapeutics, Santhera, Savara, Vertex Pharmaceuticals, Inc. (Consultant).

Doreen J. Addrizzo-Harris, MD, has no financial relationships to disclose.

Julie V. Philley, MD, has financial relationships with Insmed (Speaker's Bureau); A2N, Electromed, Insmed, Paratek (Consultant); A2N, Electromed, Hillrom, Insmed, Paratek, RedHill, Zambon (Grant/Research Support).

Patient
Patient participating in this activity has no relevant financial relationship(s) with ineligible companies to disclose.

Planners and Managers
RMEI Medical Education, LLC planners and managers have no relevant financial relationship(s) with ineligible companies to disclose.

All of the relevant financial relationships listed for these individuals have been mitigated according to RMEI policies.

Accreditation Statement

In support of improving patient care, RMEI Medical Education, LLC is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Physician Continuing Medical Education
RMEI Medical Education, LLC designates this enduring material for a maximum of 0.5 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

American Board of Internal Medicine Maintenance of Certification
Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 0.5 medical knowledge MOC point(s) in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

Criteria for Success

In order to receive credit, participants must review the activity content and successfully complete both the post-test and evaluation. A statement of credit will be available to print immediately. You must score 75% or higher on the post-test to receive credit for this activity. If you have questions about this activity, please contact RMEI at contact@rmei.com.

Users must:

  • Read the learning objectives and faculty disclosures
  • Participate in the activity
  • Complete the activity evaluation and attest to credit

In order to claim MOC point(s), users must:

  • Provide ABIM ID and month/date of birth and score 75% or higher on the post-test

MOC points will be submitted to ABIM profiles within 4 weeks of completion.

There is no fee for this educational activity.

Your Feedback is Important!

COMPLETE THE EVALUATION FORM AND YOU WILL BE ENTERED
INTO A DRAWING FOR A $100* AMAZON GIFT CARD!

*The expense for this gift card is solely funded by RMEI Medical Education, LLC.
No supporter funding was used for the expense of this gift card.

Rules and Regulations 
This sweepstakes is managed by RMEI Medical Education, LLC (RMEI), a jointly accredited provider. The winner will be selected via automated random drawing on a quarterly basis from among all eligible entries and notified through the contact information provided. In accordance with our privacy policy, we do not share your information with any third parties. By entering the sweepstakes, you grant RMEI permission to use your e-mail address to reach you for notification and prize fulfillment. Only individuals who complete the evaluation forms and provide contact information will be eligible to win. Open to those who have a US postal address and who are 18 years or older. Only one prize per person and per household will be awarded. The prize will be a $100 Amazon gift card.

Statement of Commercial Support

This activity is supported by an educational grant from Insmed.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications. The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient's conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer's product information, and comparison with recommendations of other authorities.

0.25 CME / MOC
RMEI Medical Education, LLC
A Guide to Expediting the Recognition & Diagnosis of NTM-LD

A Guide to Expediting the Recognition & Diagnosis of NTM-LD

Start
Free CME/MOC
0.25 AMA PRA Category 1 Credit(s)
0.25 ABIM MOC Point(s)
Released: July 28, 2021
Expires: July 27, 2022
15 minutes to complete

Provided By

Provided by RMEI Medical Education, LLC.

Target Audience

This activity is intended for pulmonology, infectious disease, internal medicine clinicians, and other healthcare professionals involved in the treatment of patients with nontuberculous mycobacterial lung disease (NTM-LD).

Learning Objectives

Upon completion of this activity, participants should be better able to:

  • Identify the factors that place patients at risk for developing nontuberculous mycobacterial lung disease (NTM-LD)
  • Use current guidelines to facilitate NTM-LD diagnosis

Activity Description

This learner-friendly, 15-minute infographic activity is augmented by expert and patient videos with an interactive approach to recognizing risk factors for nontuberculous mycobacterial lung disease (NTM-LD) and using guidelines to facilitate a timely diagnosis.

Chair

Patrick A. Flume, MD
Professor, Medicine and Pediatrics
Medical University of South Carolina
Charleston, SC

Faculty

Doreen J. Addrizzo-Harris, MD
Professor of Medicine
Associate Director, Clinical and Academic Affairs
Director, NYU Bronchiectasis/NTM Program
NYU Grossman School of Medicine
New York, NY


Julie V. Philley, MD
Executive Vice President, Health Affairs
University of Texas Health Science Center at Tyler
Tyler, TX

Disclosure of Financial Relationships

RMEI Medical Education, LLC (RMEI) requires instructors, planners, managers, and others in control of educational content to disclose all their financial relationships with ineligible companies over the previous 24 months. All identified financial relationships are thoroughly vetted and mitigated according to RMEI policy. RMEI is committed to providing its learners with high quality accredited continuing education activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company.

The faculty reported the following relevant financial relationships with ineligible entities related to the educational content of this CE activity:

Faculty
Patrick A. Flume, MD, has financial relationships with AbbVie, Armata, AstraZeneca, Corbus Pharmaceuticals, Cystic Fibrosis Foundation Therapeutics, Insmed, Janssen, Merck, National Institutes of Health, Novartis, Novoteris, Novovax, Proteostasis Therapeutics, Savara, Sound Pharmaceuticals, Inc., Vertex Pharmaceuticals, Inc. (Grant/Research Support); Arrevus, Chiesi, Corbus Pharmaceuticals, Eloxx Pharmaceuticals, Hill-Rom, Insmed, Ionis Pharmaceuticals, Janssen Research & Development, McKesson, Merck, Novartis, Polyphor, Proteostasis Therapeutics, Santhera, Savara, Vertex Pharmaceuticals, Inc. (Consultant).

Doreen J. Addrizzo-Harris, MD, has no financial relationships to disclose.

Julie V. Philley, MD, has financial relationships with Insmed (Speaker's Bureau); A2N, Electromed, Insmed, Paratek (Consultant); A2N, Electromed, Hillrom, Insmed, Paratek, RedHill, Zambon (Grant/Research Support).

Patient
Patient participating in this activity has no relevant financial relationship(s) with ineligible companies to disclose.

Planners and Managers
RMEI Medical Education, LLC planners and managers have no relevant financial relationship(s) with ineligible companies to disclose.

All of the relevant financial relationships listed for these individuals have been mitigated according to RMEI policies.

Accreditation Statement

In support of improving patient care, RMEI Medical Education, LLC is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Physician Continuing Medical Education
RMEI Medical Education, LLC designates this enduring material for a maximum of 0.25 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

American Board of Internal Medicine Maintenance of Certification
Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 0.25 medical knowledge MOC point(s) in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

Criteria for Success

In order to receive credit, participants must review the activity content and successfully complete both the post-test and evaluation. A statement of credit will be available to print immediately. You must score 75% or higher on the post-test to receive credit for this activity. If you have questions about this activity, please contact RMEI at contact@rmei.com.

Users must:

  • Read the learning objectives and faculty disclosures
  • Participate in the activity
  • Complete the activity evaluation and attest to credit

In order to claim MOC point(s), users must:

  • Provide ABIM ID and month/date of birth and score 75% or higher on the post-test

MOC points will be submitted to ABIM profiles within 4 weeks of completion.

There is no fee to participate.

Your Feedback is Important!

COMPLETE THE EVALUATION FORM AND YOU WILL BE ENTERED
INTO A DRAWING FOR A $100* AMAZON GIFT CARD!

*The expense for this gift card is solely funded by RMEI Medical Education, LLC.
No supporter funding was used for the expense of this gift card.

Rules and Regulations 
This sweepstakes is managed by RMEI Medical Education, LLC (RMEI), a jointly accredited provider. The winner will be selected via automated random drawing on a quarterly basis from among all eligible entries and notified through the contact information provided. In accordance with our privacy policy, we do not share your information with any third parties. By entering the sweepstakes, you grant RMEI permission to use your e-mail address to reach you for notification and prize fulfillment. Only individuals who complete the evaluation forms and provide contact information will be eligible to win. Open to those who have a US postal address and who are 18 years or older. Only one prize per person and per household will be awarded. The prize will be a $100 Amazon gift card.

Statement of Commercial Support

This activity is supported by an educational grant from Insmed.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications. The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient's conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer's product information, and comparison with recommendations of other authorities.

Free CME/MOC
0.25 AMA PRA Category 1 Credit(s)
0.25 ABIM MOC Point(s)
Released: July 28, 2021
Expires: July 27, 2022
15 minutes to complete

Provided By

Provided by RMEI Medical Education, LLC.

Target Audience

This activity is intended for pulmonology, infectious disease, internal medicine clinicians, and other healthcare professionals involved in the treatment of patients with nontuberculous mycobacterial lung disease (NTM-LD).

Learning Objectives

Upon completion of this activity, participants should be better able to:

  • Identify the factors that place patients at risk for developing nontuberculous mycobacterial lung disease (NTM-LD)
  • Use current guidelines to facilitate NTM-LD diagnosis

Activity Description

This learner-friendly, 15-minute infographic activity is augmented by expert and patient videos with an interactive approach to recognizing risk factors for nontuberculous mycobacterial lung disease (NTM-LD) and using guidelines to facilitate a timely diagnosis.

Chair

Patrick A. Flume, MD
Professor, Medicine and Pediatrics
Medical University of South Carolina
Charleston, SC

Faculty

Doreen J. Addrizzo-Harris, MD
Professor of Medicine
Associate Director, Clinical and Academic Affairs
Director, NYU Bronchiectasis/NTM Program
NYU Grossman School of Medicine
New York, NY


Julie V. Philley, MD
Executive Vice President, Health Affairs
University of Texas Health Science Center at Tyler
Tyler, TX

Disclosure of Financial Relationships

RMEI Medical Education, LLC (RMEI) requires instructors, planners, managers, and others in control of educational content to disclose all their financial relationships with ineligible companies over the previous 24 months. All identified financial relationships are thoroughly vetted and mitigated according to RMEI policy. RMEI is committed to providing its learners with high quality accredited continuing education activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company.

The faculty reported the following relevant financial relationships with ineligible entities related to the educational content of this CE activity:

Faculty
Patrick A. Flume, MD, has financial relationships with AbbVie, Armata, AstraZeneca, Corbus Pharmaceuticals, Cystic Fibrosis Foundation Therapeutics, Insmed, Janssen, Merck, National Institutes of Health, Novartis, Novoteris, Novovax, Proteostasis Therapeutics, Savara, Sound Pharmaceuticals, Inc., Vertex Pharmaceuticals, Inc. (Grant/Research Support); Arrevus, Chiesi, Corbus Pharmaceuticals, Eloxx Pharmaceuticals, Hill-Rom, Insmed, Ionis Pharmaceuticals, Janssen Research & Development, McKesson, Merck, Novartis, Polyphor, Proteostasis Therapeutics, Santhera, Savara, Vertex Pharmaceuticals, Inc. (Consultant).

Doreen J. Addrizzo-Harris, MD, has no financial relationships to disclose.

Julie V. Philley, MD, has financial relationships with Insmed (Speaker's Bureau); A2N, Electromed, Insmed, Paratek (Consultant); A2N, Electromed, Hillrom, Insmed, Paratek, RedHill, Zambon (Grant/Research Support).

Patient
Patient participating in this activity has no relevant financial relationship(s) with ineligible companies to disclose.

Planners and Managers
RMEI Medical Education, LLC planners and managers have no relevant financial relationship(s) with ineligible companies to disclose.

All of the relevant financial relationships listed for these individuals have been mitigated according to RMEI policies.

Accreditation Statement

In support of improving patient care, RMEI Medical Education, LLC is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Physician Continuing Medical Education
RMEI Medical Education, LLC designates this enduring material for a maximum of 0.25 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

American Board of Internal Medicine Maintenance of Certification
Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 0.25 medical knowledge MOC point(s) in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

Criteria for Success

In order to receive credit, participants must review the activity content and successfully complete both the post-test and evaluation. A statement of credit will be available to print immediately. You must score 75% or higher on the post-test to receive credit for this activity. If you have questions about this activity, please contact RMEI at contact@rmei.com.

Users must:

  • Read the learning objectives and faculty disclosures
  • Participate in the activity
  • Complete the activity evaluation and attest to credit

In order to claim MOC point(s), users must:

  • Provide ABIM ID and month/date of birth and score 75% or higher on the post-test

MOC points will be submitted to ABIM profiles within 4 weeks of completion.

There is no fee to participate.

Your Feedback is Important!

COMPLETE THE EVALUATION FORM AND YOU WILL BE ENTERED
INTO A DRAWING FOR A $100* AMAZON GIFT CARD!

*The expense for this gift card is solely funded by RMEI Medical Education, LLC.
No supporter funding was used for the expense of this gift card.

Rules and Regulations 
This sweepstakes is managed by RMEI Medical Education, LLC (RMEI), a jointly accredited provider. The winner will be selected via automated random drawing on a quarterly basis from among all eligible entries and notified through the contact information provided. In accordance with our privacy policy, we do not share your information with any third parties. By entering the sweepstakes, you grant RMEI permission to use your e-mail address to reach you for notification and prize fulfillment. Only individuals who complete the evaluation forms and provide contact information will be eligible to win. Open to those who have a US postal address and who are 18 years or older. Only one prize per person and per household will be awarded. The prize will be a $100 Amazon gift card.

Statement of Commercial Support

This activity is supported by an educational grant from Insmed.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications. The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient's conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer's product information, and comparison with recommendations of other authorities.

1.00 CME / CNE / CPE
The Postgraduate Institute for Medicine
Navigating the Complexity of Pulmonary Arterial Hypertension: Advances in the Diagnosis and Management – Part II: PAH Treatment - Goals, Therapeutic Options, and Guidelines

Navigating the Complexity of Pulmonary Arterial Hypertension: Advances in the Diagnosis and Management – Part II: PAH Treatment - Goals, Therapeutic Options, and Guidelines

Start

Activity Details

Free CME/CNE/CPE
1 AMA PRA Category 1 Credit(s)
1 contact hour(s)
Released: June 17, 2021
Expires: June 17, 2022
60 minutes to complete

Accredited By

Target Audience

The activity will target a global audience of cardiologists, lipidologists, primary care physicians, nurses, physician assistants, and pharmacists.

Learning Objectives

  • Incorporate risk stratification methods for selecting and modifying therapy in patients with PAH
  • Evaluate the efficacy and safety of current and emerging therapeutic options for PAH
  • Review the evidence for initiating combination therapy in patients with PAH

Faculty

Nazzareno Galiè, MD
Professore Ordinario di Cardiologia
Direttore U.O.C. di Cardiologia, IRCCS-Policlinico di S.Orsola, Bologna
Direttore della Scuola di Specializzazione in
Malattie dell’Apparato Cardiovascolare
Bologna, Italy

Dr. Galiè discloses the following:
Consulting Fees: Janssen, Actelion, Ferrer, Pfizer
Contracted Research: Janssen

Gerald Simonneau, MD
French Reference Center for PH
Emeritus Professor University Paris-Saclay
Paris, France

Dr. Simonneau discloses the following:
Consulting Fees: Actelion, Bayer, MSA
Fees for Non-CME Services Received Directly from a Commercial Interest: Actelion, Bayer, MSA

Conflict of Interest Policy/Disclosure Statement

Postgraduate Institute for Medicine (PIM) requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose any real or apparent conflict of interest (COI) they may have as related to the content of this activity. All identified COI are thoroughly vetted and resolved according to PIM policy. PIM is committed to providing its learners with high quality activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of a commercial interest.

Planners and Managers
The PIM planners and managers have nothing to disclose.
The CMHC planners and managers have nothing to disclose.

Joint Accreditation Statement

In support of improving patient care, this activity has been planned and implemented by the Postgraduate Institute for Medicine and Tarsus Cardio Inc. dba Cardiometabolic Health Congress (CMHC). Postgraduate Institute for Medicine is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

PHYSICIAN CONTINUING MEDICAL EDUCATION
The Postgraduate Institute for Medicine designates this enduring material for a maximum of 1 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credits commensurate with the extent of their participation in the activity.

CONTINUING NURSING EDUCATION
The maximum number of hours awarded for this Continuing Nursing Education activity is 1 contact hour(s). Pharmacotherapy contact hours for Advanced Practice Registered Nurses will be designated on your certificate.

CONTINUING PHARMACY EDUCATION
Postgraduate Institute for Medicine designates this continuing education activity for 1 contact hour(s) (0.1 CEUs) of the Accreditation Council for Pharmacy Education.

This is a knowledge-based activity. Universal Activity Numbers (UAN): # JA4008162-9999-21-2780-H01-P

For Pharmacists: Upon completing the post-test and the activity evaluation form, transcript information will be sent to the NABP CPE Monitor Service within 4 – 6 weeks.

Statement of Commercial Support

Supported by an educational grant from Merck Sharp & Dohme Corp.

Disclaimer Statement/Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications. The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Contact Information for Questions About the Activity

For questions about the accreditation of this activity, please visit www.pimed.com.

Activity Details

Free CME/CNE/CPE
1 AMA PRA Category 1 Credit(s)
1 contact hour(s)
Released: June 17, 2021
Expires: June 17, 2022
60 minutes to complete

Accredited By

Target Audience

The activity will target a global audience of cardiologists, lipidologists, primary care physicians, nurses, physician assistants, and pharmacists.

Learning Objectives

  • Incorporate risk stratification methods for selecting and modifying therapy in patients with PAH
  • Evaluate the efficacy and safety of current and emerging therapeutic options for PAH
  • Review the evidence for initiating combination therapy in patients with PAH

Faculty

Nazzareno Galiè, MD
Professore Ordinario di Cardiologia
Direttore U.O.C. di Cardiologia, IRCCS-Policlinico di S.Orsola, Bologna
Direttore della Scuola di Specializzazione in
Malattie dell’Apparato Cardiovascolare
Bologna, Italy

Dr. Galiè discloses the following:
Consulting Fees: Janssen, Actelion, Ferrer, Pfizer
Contracted Research: Janssen

Gerald Simonneau, MD
French Reference Center for PH
Emeritus Professor University Paris-Saclay
Paris, France

Dr. Simonneau discloses the following:
Consulting Fees: Actelion, Bayer, MSA
Fees for Non-CME Services Received Directly from a Commercial Interest: Actelion, Bayer, MSA

Conflict of Interest Policy/Disclosure Statement

Postgraduate Institute for Medicine (PIM) requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose any real or apparent conflict of interest (COI) they may have as related to the content of this activity. All identified COI are thoroughly vetted and resolved according to PIM policy. PIM is committed to providing its learners with high quality activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of a commercial interest.

Planners and Managers
The PIM planners and managers have nothing to disclose.
The CMHC planners and managers have nothing to disclose.

Joint Accreditation Statement

In support of improving patient care, this activity has been planned and implemented by the Postgraduate Institute for Medicine and Tarsus Cardio Inc. dba Cardiometabolic Health Congress (CMHC). Postgraduate Institute for Medicine is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

PHYSICIAN CONTINUING MEDICAL EDUCATION
The Postgraduate Institute for Medicine designates this enduring material for a maximum of 1 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credits commensurate with the extent of their participation in the activity.

CONTINUING NURSING EDUCATION
The maximum number of hours awarded for this Continuing Nursing Education activity is 1 contact hour(s). Pharmacotherapy contact hours for Advanced Practice Registered Nurses will be designated on your certificate.

CONTINUING PHARMACY EDUCATION
Postgraduate Institute for Medicine designates this continuing education activity for 1 contact hour(s) (0.1 CEUs) of the Accreditation Council for Pharmacy Education.

This is a knowledge-based activity. Universal Activity Numbers (UAN): # JA4008162-9999-21-2780-H01-P

For Pharmacists: Upon completing the post-test and the activity evaluation form, transcript information will be sent to the NABP CPE Monitor Service within 4 – 6 weeks.

Statement of Commercial Support

Supported by an educational grant from Merck Sharp & Dohme Corp.

Disclaimer Statement/Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications. The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Contact Information for Questions About the Activity

For questions about the accreditation of this activity, please visit www.pimed.com.

1.00 CME / CNE / CPE
The Postgraduate Institute for Medicine
Navigating the Complexity of Pulmonary Arterial Hypertension: Advances in the Diagnosis and Management – Part III: Latest Data on PAH Treatment Approaches

Navigating the Complexity of Pulmonary Arterial Hypertension: Advances in the Diagnosis and Management – Part III: Latest Data on PAH Treatment Approaches

Start

Activity Details

Free CME/CNE/CPE
1 AMA PRA Category 1 Credit(s)
1 contact hour(s)
Released: June 17, 2021
Expires: June 17, 2022
60 minutes to complete

Accredited By

Target Audience

The activity will target a global audience of cardiologists, lipidologists, primary care physicians, nurses, physician assistants, and pharmacists.

Learning Objectives

  • Evaluate the potential role of cardiac MRI metrics and other cardiac endpoints in PAH risk stratification
  • Interpret the results of recent trials for transition of PAH therapies
  • Summarize real-world data from PAH registries and their potential implications for management

Faculty

Vallerie V. McLaughlin, MD
Professor of Cardiovascular Medicine
Director of the Pulmonary Hypertension Program
University of Michigan
Ann Arbor, MI

Dr. McLaughlin discloses the following:
Consulting Fees: Acceleron, Actelion, Altavant, Caremark, Civi Biopharma, Gossamer, Liquida, United Therapeutics
Contracted Research: Acceleron, Actelion, Gilead, Sonivie, Reata, United Therapeutics

Stephan Rosenkranz, MD
Professor
Department of Cardiology, Pulmonology, and Intensive Care Medicine
Center for Molecular Medicine Cologne (CMMC)
Cologne Cardiovascular Research Center (CCRC)
Heart Center at the University of Cologne
Cologne, Germany

Dr. Rosenkranz discloses the following:
Consulting Fees and Fees for Non-CME Services Received Directly from a Commercial Interest: Abbott, Acceleron, Actelion, Bayer, BMS, MSD, Novartis, Pfizer, Ferrer, United Therapeutics, Vifor
Contracted Research to Institution: Actelion, AstraZeneca, Bayer, Novartis, Pfizer, Janssen

Conflict of Interest Policy/Disclosure Statement

Postgraduate Institute for Medicine (PIM) requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose any real or apparent conflict of interest (COI) they may have as related to the content of this activity. All identified COI are thoroughly vetted and resolved according to PIM policy. PIM is committed to providing its learners with high quality activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of a commercial interest.

Planners and Managers
The PIM planners and managers have nothing to disclose.
The CMHC planners and managers have nothing to disclose.

Joint Accreditation Statement

In support of improving patient care, this activity has been planned and implemented by the Postgraduate Institute for Medicine and Tarsus Cardio Inc. dba Cardiometabolic Health Congress (CMHC). Postgraduate Institute for Medicine is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

PHYSICIAN CONTINUING MEDICAL EDUCATION
The Postgraduate Institute for Medicine designates this enduring material for a maximum of 1 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credits commensurate with the extent of their participation in the activity.

CONTINUING NURSING EDUCATION
The maximum number of hours awarded for this Continuing Nursing Education activity is 1 contact hour(s). Pharmacotherapy contact hours for Advanced Practice Registered Nurses will be designated on your certificate.

CONTINUING PHARMACY EDUCATION
Postgraduate Institute for Medicine designates this continuing education activity for 1 contact hour(s) (0.1 CEUs) of the Accreditation Council for Pharmacy Education.

This is a knowledge-based activity. Universal Activity Numbers (UAN): # JA4008162-9999-21-2781-H01-P

For Pharmacists: Upon completing the post-test and the activity evaluation form, transcript information will be sent to the NABP CPE Monitor Service within 4 – 6 weeks.

Statement of Commercial Support

Supported by an educational grant from Merck Sharp & Dohme Corp.

Disclaimer Statement/Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications. The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Contact Information for Questions About the Activity

For questions about the accreditation of this activity, please visit www.pimed.com.

Activity Details

Free CME/CNE/CPE
1 AMA PRA Category 1 Credit(s)
1 contact hour(s)
Released: June 17, 2021
Expires: June 17, 2022
60 minutes to complete

Accredited By

Target Audience

The activity will target a global audience of cardiologists, lipidologists, primary care physicians, nurses, physician assistants, and pharmacists.

Learning Objectives

  • Evaluate the potential role of cardiac MRI metrics and other cardiac endpoints in PAH risk stratification
  • Interpret the results of recent trials for transition of PAH therapies
  • Summarize real-world data from PAH registries and their potential implications for management

Faculty

Vallerie V. McLaughlin, MD
Professor of Cardiovascular Medicine
Director of the Pulmonary Hypertension Program
University of Michigan
Ann Arbor, MI

Dr. McLaughlin discloses the following:
Consulting Fees: Acceleron, Actelion, Altavant, Caremark, Civi Biopharma, Gossamer, Liquida, United Therapeutics
Contracted Research: Acceleron, Actelion, Gilead, Sonivie, Reata, United Therapeutics

Stephan Rosenkranz, MD
Professor
Department of Cardiology, Pulmonology, and Intensive Care Medicine
Center for Molecular Medicine Cologne (CMMC)
Cologne Cardiovascular Research Center (CCRC)
Heart Center at the University of Cologne
Cologne, Germany

Dr. Rosenkranz discloses the following:
Consulting Fees and Fees for Non-CME Services Received Directly from a Commercial Interest: Abbott, Acceleron, Actelion, Bayer, BMS, MSD, Novartis, Pfizer, Ferrer, United Therapeutics, Vifor
Contracted Research to Institution: Actelion, AstraZeneca, Bayer, Novartis, Pfizer, Janssen

Conflict of Interest Policy/Disclosure Statement

Postgraduate Institute for Medicine (PIM) requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose any real or apparent conflict of interest (COI) they may have as related to the content of this activity. All identified COI are thoroughly vetted and resolved according to PIM policy. PIM is committed to providing its learners with high quality activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of a commercial interest.

Planners and Managers
The PIM planners and managers have nothing to disclose.
The CMHC planners and managers have nothing to disclose.

Joint Accreditation Statement

In support of improving patient care, this activity has been planned and implemented by the Postgraduate Institute for Medicine and Tarsus Cardio Inc. dba Cardiometabolic Health Congress (CMHC). Postgraduate Institute for Medicine is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

PHYSICIAN CONTINUING MEDICAL EDUCATION
The Postgraduate Institute for Medicine designates this enduring material for a maximum of 1 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credits commensurate with the extent of their participation in the activity.

CONTINUING NURSING EDUCATION
The maximum number of hours awarded for this Continuing Nursing Education activity is 1 contact hour(s). Pharmacotherapy contact hours for Advanced Practice Registered Nurses will be designated on your certificate.

CONTINUING PHARMACY EDUCATION
Postgraduate Institute for Medicine designates this continuing education activity for 1 contact hour(s) (0.1 CEUs) of the Accreditation Council for Pharmacy Education.

This is a knowledge-based activity. Universal Activity Numbers (UAN): # JA4008162-9999-21-2781-H01-P

For Pharmacists: Upon completing the post-test and the activity evaluation form, transcript information will be sent to the NABP CPE Monitor Service within 4 – 6 weeks.

Statement of Commercial Support

Supported by an educational grant from Merck Sharp & Dohme Corp.

Disclaimer Statement/Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications. The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Contact Information for Questions About the Activity

For questions about the accreditation of this activity, please visit www.pimed.com.

1.00 CME / CNE / CPE
The Postgraduate Institute for Medicine
Navigating the Complexity of Pulmonary Arterial Hypertension: Advances in the Diagnosis and Management – Part IV: Patient Cases: Putting Evidence Into Perspective

Navigating the Complexity of Pulmonary Arterial Hypertension: Advances in the Diagnosis and Management – Part IV: Patient Cases: Putting Evidence Into Perspective

Start

Activity Details

Free CME/CNE/CPE
1 AMA PRA Category 1 Credit(s)
1 contact hour(s)
Released: June 17, 2021
Expires: June 17, 2022
60 minutes to complete

Accredited By

Target Audience

The activity will target a global audience of cardiologists, lipidologists, primary care physicians, nurses, physician assistants, and pharmacists.

Learning Objectives

  • Summarize the current guidelines and recommendations for the treatment of PAH
  • Develop individualized treatment regimens based on the multidisciplinary approach to care for PAH that takes into account treatment goals, short-and-long-term assessment, and comorbidities in order to improve patient outcomes

Faculty

Sonja Bartolome, MD, FCCP
Professor, Pulmonary and Critical Care Medicine
Associate Chief Quality Officer
UT Southwestern Medical Center
Dallas, TX

Dr. Bartolome discloses the following:
Consulting Fees: Janssen

Ronald J. Oudiz, MD, FACP, FACC, FCCP
Investigator, The Lundquist Institute
Professor of Medicine, David Geffen School of Medicine at UCLA
Director, Liu Center for Pulmonary Hypertension, The Lundquist Institute
Torrance, CA

Dr. Oudiz discloses the following:
Consulting Fees: Gilead, Gossamer, Insmed, JnJ, Liquidia, Respira, United Therapeutics, V-Wave
Fees for Non-CME Services Received Directly from a Commercial Interest: JnJ, United Therapeutics, V-Wave
Contracted Research: AADi, Gossamer, Insmed, JnJ, Liquidia, United Therapeutics, V-Wave

Conflict of Interest Policy/Disclosure Statement

Postgraduate Institute for Medicine (PIM) requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose any real or apparent conflict of interest (COI) they may have as related to the content of this activity. All identified COI are thoroughly vetted and resolved according to PIM policy. PIM is committed to providing its learners with high quality activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of a commercial interest.

Planners and Managers
The PIM planners and managers have nothing to disclose.
The CMHC planners and managers have nothing to disclose.

Joint Accreditation Statement

In support of improving patient care, this activity has been planned and implemented by the Postgraduate Institute for Medicine and Tarsus Cardio Inc. dba Cardiometabolic Health Congress (CMHC). Postgraduate Institute for Medicine is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

PHYSICIAN CONTINUING MEDICAL EDUCATION
The Postgraduate Institute for Medicine designates this enduring material for a maximum of 1 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credits commensurate with the extent of their participation in the activity.

CONTINUING NURSING EDUCATION
The maximum number of hours awarded for this Continuing Nursing Education activity is 1 contact hour(s). Pharmacotherapy contact hours for Advanced Practice Registered Nurses will be designated on your certificate.

CONTINUING PHARMACY EDUCATION
Postgraduate Institute for Medicine designates this continuing education activity for 1 contact hour(s) (0.1 CEUs) of the Accreditation Council for Pharmacy Education.

This is a knowledge-based activity. Universal Activity Numbers (UAN): # JA4008162-9999-21-2782-H01-P

For Pharmacists: Upon completing the post-test and the activity evaluation form, transcript information will be sent to the NABP CPE Monitor Service within 4 – 6 weeks.

Statement of Commercial Support

Supported by an educational grant from Merck Sharp & Dohme Corp.

Disclaimer Statement/Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications. The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Contact Information for Questions About the Activity

For questions about the accreditation of this activity, please visit www.pimed.com.

Activity Details

Free CME/CNE/CPE
1 AMA PRA Category 1 Credit(s)
1 contact hour(s)
Released: June 17, 2021
Expires: June 17, 2022
60 minutes to complete

Accredited By

Target Audience

The activity will target a global audience of cardiologists, lipidologists, primary care physicians, nurses, physician assistants, and pharmacists.

Learning Objectives

  • Summarize the current guidelines and recommendations for the treatment of PAH
  • Develop individualized treatment regimens based on the multidisciplinary approach to care for PAH that takes into account treatment goals, short-and-long-term assessment, and comorbidities in order to improve patient outcomes

Faculty

Sonja Bartolome, MD, FCCP
Professor, Pulmonary and Critical Care Medicine
Associate Chief Quality Officer
UT Southwestern Medical Center
Dallas, TX

Dr. Bartolome discloses the following:
Consulting Fees: Janssen

Ronald J. Oudiz, MD, FACP, FACC, FCCP
Investigator, The Lundquist Institute
Professor of Medicine, David Geffen School of Medicine at UCLA
Director, Liu Center for Pulmonary Hypertension, The Lundquist Institute
Torrance, CA

Dr. Oudiz discloses the following:
Consulting Fees: Gilead, Gossamer, Insmed, JnJ, Liquidia, Respira, United Therapeutics, V-Wave
Fees for Non-CME Services Received Directly from a Commercial Interest: JnJ, United Therapeutics, V-Wave
Contracted Research: AADi, Gossamer, Insmed, JnJ, Liquidia, United Therapeutics, V-Wave

Conflict of Interest Policy/Disclosure Statement

Postgraduate Institute for Medicine (PIM) requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose any real or apparent conflict of interest (COI) they may have as related to the content of this activity. All identified COI are thoroughly vetted and resolved according to PIM policy. PIM is committed to providing its learners with high quality activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of a commercial interest.

Planners and Managers
The PIM planners and managers have nothing to disclose.
The CMHC planners and managers have nothing to disclose.

Joint Accreditation Statement

In support of improving patient care, this activity has been planned and implemented by the Postgraduate Institute for Medicine and Tarsus Cardio Inc. dba Cardiometabolic Health Congress (CMHC). Postgraduate Institute for Medicine is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

PHYSICIAN CONTINUING MEDICAL EDUCATION
The Postgraduate Institute for Medicine designates this enduring material for a maximum of 1 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credits commensurate with the extent of their participation in the activity.

CONTINUING NURSING EDUCATION
The maximum number of hours awarded for this Continuing Nursing Education activity is 1 contact hour(s). Pharmacotherapy contact hours for Advanced Practice Registered Nurses will be designated on your certificate.

CONTINUING PHARMACY EDUCATION
Postgraduate Institute for Medicine designates this continuing education activity for 1 contact hour(s) (0.1 CEUs) of the Accreditation Council for Pharmacy Education.

This is a knowledge-based activity. Universal Activity Numbers (UAN): # JA4008162-9999-21-2782-H01-P

For Pharmacists: Upon completing the post-test and the activity evaluation form, transcript information will be sent to the NABP CPE Monitor Service within 4 – 6 weeks.

Statement of Commercial Support

Supported by an educational grant from Merck Sharp & Dohme Corp.

Disclaimer Statement/Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications. The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Contact Information for Questions About the Activity

For questions about the accreditation of this activity, please visit www.pimed.com.

1.00 CME / CNE / CPE
The Postgraduate Institute for Medicine
Navigating the Complexity of Pulmonary Arterial Hypertension: Advances in the Diagnosis and Management – Part I: Screening and Diagnosis of PAH

Navigating the Complexity of Pulmonary Arterial Hypertension: Advances in the Diagnosis and Management – Part I: Screening and Diagnosis of PAH

Start

Activity Details

Free CME/CNE/CPE
1 AMA PRA Category 1 Credit(s)
1 contact hour(s)
Released: June 17, 2021
Expires: June 17, 2022
60 minutes to complete

Accredited By

Target Audience

The activity will target a global audience of cardiologists, lipidologists, primary care physicians, nurses, physician assistants, and pharmacists.

Learning Objectives

  • Identify patients with PAH based on symptoms, risk factors, and screening strategies outlined in evidence-based guidelines
  • Utilize evidence-based diagnostic methods to effectively and timely diagnose PAH patients

Faculty

Jean Elwing, MD, FCCP
Professor of Medicine
University of Cincinnati
Pulmonary Hypertension Program
Cincinnati, OH

Dr. Elwing discloses the following:
Consulting Fees: United Therapeutics, Acceleron, Liquidia, Altavant, Bayer, Gossamer Bio
Contracted Research: Actelion, Acceleron, Reata, United Therapeutics, Liquidia, Phase Bio, Complexa, Gossamer Bio, Bayer

Marc Humbert, MD, PhD
Centre National de Référence de l’Hypertension Pulmonaire Sévère
Hôpital Bicêtre
Assistance Publique – Hôpitaux de Paris
Université Paris-Saclay
Le Kremlin-Bicêtre, France

Dr. Humbert discloses the following:
Consulting Fees: Acceleron, Bayer, GSK, Janssen, Merck
Contracted Research: Acceleron, Bayer, GSK, Janssen, Merck

Conflict of Interest Policy/Disclosure Statement

Postgraduate Institute for Medicine (PIM) requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose any real or apparent conflict of interest (COI) they may have as related to the content of this activity. All identified COI are thoroughly vetted and resolved according to PIM policy. PIM is committed to providing its learners with high quality activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of a commercial interest.

Planners and Managers
The PIM planners and managers have nothing to disclose.
The CMHC planners and managers have nothing to disclose.

Joint Accreditation Statement

In support of improving patient care, this activity has been planned and implemented by the Postgraduate Institute for Medicine and Tarsus Cardio Inc. dba Cardiometabolic Health Congress (CMHC). Postgraduate Institute for Medicine is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

PHYSICIAN CONTINUING MEDICAL EDUCATION
The Postgraduate Institute for Medicine designates this enduring material for a maximum of 1 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credits commensurate with the extent of their participation in the activity.

CONTINUING NURSING EDUCATION
The maximum number of hours awarded for this Continuing Nursing Education activity is 1 contact hour(s). Pharmacotherapy contact hours for Advanced Practice Registered Nurses will be designated on your certificate.

CONTINUING PHARMACY EDUCATION
Postgraduate Institute for Medicine designates this continuing education activity for 1 contact hour(s) (0.1 CEUs) of the Accreditation Council for Pharmacy Education.

This is a knowledge-based activity. Universal Activity Numbers (UAN): # JA4008162-9999-21-2779-H01-P

For Pharmacists: Upon completing the post-test and the activity evaluation form, transcript information will be sent to the NABP CPE Monitor Service within 4 – 6 weeks.

Statement of Commercial Support

Supported by an educational grant from Merck Sharp & Dohme Corp.

Disclaimer Statement/Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications. The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Contact Information for Questions About the Activity

For questions about the accreditation of this activity, please visit www.pimed.com.

Activity Details

Free CME/CNE/CPE
1 AMA PRA Category 1 Credit(s)
1 contact hour(s)
Released: June 17, 2021
Expires: June 17, 2022
60 minutes to complete

Accredited By

Target Audience

The activity will target a global audience of cardiologists, lipidologists, primary care physicians, nurses, physician assistants, and pharmacists.

Learning Objectives

  • Identify patients with PAH based on symptoms, risk factors, and screening strategies outlined in evidence-based guidelines
  • Utilize evidence-based diagnostic methods to effectively and timely diagnose PAH patients

Faculty

Jean Elwing, MD, FCCP
Professor of Medicine
University of Cincinnati
Pulmonary Hypertension Program
Cincinnati, OH

Dr. Elwing discloses the following:
Consulting Fees: United Therapeutics, Acceleron, Liquidia, Altavant, Bayer, Gossamer Bio
Contracted Research: Actelion, Acceleron, Reata, United Therapeutics, Liquidia, Phase Bio, Complexa, Gossamer Bio, Bayer

Marc Humbert, MD, PhD
Centre National de Référence de l’Hypertension Pulmonaire Sévère
Hôpital Bicêtre
Assistance Publique – Hôpitaux de Paris
Université Paris-Saclay
Le Kremlin-Bicêtre, France

Dr. Humbert discloses the following:
Consulting Fees: Acceleron, Bayer, GSK, Janssen, Merck
Contracted Research: Acceleron, Bayer, GSK, Janssen, Merck

Conflict of Interest Policy/Disclosure Statement

Postgraduate Institute for Medicine (PIM) requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose any real or apparent conflict of interest (COI) they may have as related to the content of this activity. All identified COI are thoroughly vetted and resolved according to PIM policy. PIM is committed to providing its learners with high quality activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of a commercial interest.

Planners and Managers
The PIM planners and managers have nothing to disclose.
The CMHC planners and managers have nothing to disclose.

Joint Accreditation Statement

In support of improving patient care, this activity has been planned and implemented by the Postgraduate Institute for Medicine and Tarsus Cardio Inc. dba Cardiometabolic Health Congress (CMHC). Postgraduate Institute for Medicine is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

PHYSICIAN CONTINUING MEDICAL EDUCATION
The Postgraduate Institute for Medicine designates this enduring material for a maximum of 1 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credits commensurate with the extent of their participation in the activity.

CONTINUING NURSING EDUCATION
The maximum number of hours awarded for this Continuing Nursing Education activity is 1 contact hour(s). Pharmacotherapy contact hours for Advanced Practice Registered Nurses will be designated on your certificate.

CONTINUING PHARMACY EDUCATION
Postgraduate Institute for Medicine designates this continuing education activity for 1 contact hour(s) (0.1 CEUs) of the Accreditation Council for Pharmacy Education.

This is a knowledge-based activity. Universal Activity Numbers (UAN): # JA4008162-9999-21-2779-H01-P

For Pharmacists: Upon completing the post-test and the activity evaluation form, transcript information will be sent to the NABP CPE Monitor Service within 4 – 6 weeks.

Statement of Commercial Support

Supported by an educational grant from Merck Sharp & Dohme Corp.

Disclaimer Statement/Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications. The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Contact Information for Questions About the Activity

For questions about the accreditation of this activity, please visit www.pimed.com.

2.00 CME
The Academy for Continued Healthcare Learning
Hard to Swallow: Bridging Knowledge Gaps in Eosinophilic Esophagitis

Hard to Swallow: Bridging Knowledge Gaps in Eosinophilic Esophagitis

Start

Activity Details

Free CME
2.0 AMA PRA Category 1 Credit(s)
Released: June 4, 2021
Expires: June 4, 2022
120 minutes to complete

Accredited By

Target Audience

This activity is intended for gastroenterologists, allergists, primary care physicians, pediatricians, advanced practice providers, and nurses who care for patients with swallowing disorder.

Learning Objectives

Upon completion of this activity, participants will be able to:

  • Identify patients with EoE using the latest diagnostic recommendations and criteria
  • Outline the reasoning for why EoE must be viewed as a chronic rather than an acute disease
  • Incorporate strategies to facilitate coordinated interdisciplinary EoE care among gastroenterologists, allergists, and nutritionists
  • Evaluate the latest safety and efficacy data with the therapies in clinical trials for EoE
  • Indicate the potential roles of investigational treatments in EoE management plans

Activity Description

Did you know that the incidence of eosinophilic esophagitis (EoE) is increasing rapidly? Are you familiar with the burdens faced by adult and pediatric patients living with EoE? In this multi-module activity led by an interdisciplinary panel, access practical guidance and supplemental resources on the management and treatment of EoE. Navigate at your own pace through video modules and an interactive infographic with animated content and expert commentary.

Faculty discussion will focus on:

  • Recognizing and diagnosing EoE
  • Treating EoE as a chronic disease
  • Novel developments in treatment

Statement of Educational Need

EoE is an immune-mediated, chronic disease that has been steadily increasing in prevalence and incidence over the past 30 years. Clinicians need to understand that the natural history of the EoE consists of chronic inflammation that may progress into fibrous remodeling. Problematically, EoE diagnosis can be challenging for clinicians, and is often considered the last diagnosis. Thus, clinicians need to be more aware of EoE to decrease diagnostic delays. This activity will also raise awareness that EoE is a chronic disease that requires extended therapy and educate clinicians on emerging therapeutic options and the newest guidelines. Finally, clinicians need to improve their multidisciplinary management of EoE to improve outcomes.

Agenda

Video Module - Introduction to EoE and Its Diagnosis
Video Module - EoE: A Chronic Disease With Unmet Treatment Needs
Video Module - It Takes a Village: Interdisciplinary Care for EoE
Interactive Infographic - Practical Points for the Diagnosis and Chronic Treatment of EoE

Faculty

Evan Dellon, MD, MPH
Department of Medicine
Division of Gastroenterology and Hepatology
Adjunct Professor of Epidemiology
Director, CGIBD Biostatistics and Clinical Research Core
Director, Center for Esophageal Diseases and Swallowing
School of Medicine, University of North Carolina at Chapel Hill
Chapel Hill, NC

Raquel Durban, MS, RD, CSP, LDN
Carolina Asthma & Allergy Center
Registered Dietitian
Charlotte, NC

Gary W. Falk, MD, MS
Professor of Medicine
Division of Gastroenterology
University of Pennsylvania Perelman School of Medicine
Philadelphia, PA

Calies Menard-Katcher, MD, MSCS
Associate Professor of Pediatrics
Associate Director of Clinical Research for the GEDP
Division of Gastroenterology Hepatology and Nutrition
Department of Pediatrics
University of Colorado School of Medicine
Gastrointestinal Eosinophilic Diseases Program
Digestive Health Institute
Children's Hospital Colorado
Aurora, CO

Robert Pesek, MD
Medical Director, Asthma
Medical Director, Eosinophilic Gastrointestinal Disorders Clinic
Associate Professor of Pediatrics and Allergy/Immunology
Arkansas Children's Hospital and the University of Arkansas for Medical Sciences
Little Rock, AR

The Academy for Continued Healthcare Learning (ACHL) requires that the faculty participating in an accredited continuing education activity disclose all affiliations or other financial relationships (1) with the manufacturers of any commercial product(s) and/or provider(s) of commercial services discussed in an educational presentation and (2) with any commercial supporters of the activity. All conflicts of interest have been mitigated prior to this activity.

The following financial relationships have been provided:

Evan Dellon, MD, MPH
Consultant (Occasional): Abbott, Adare/Ellodi, Aimmune, Allakos, Amgen, Arena, AstraZeneca, Avir, Biorasi, Calypso, Celgene/Receptos/Bristol Myers Squibb, Celldex, Eli Lilly, EsoCap, GlaxoSmithKline, Gossamer Bio, Parexel, Regeneron, Robarts/Alimentiv, Salix, Sanofi, Shire/Takeda
Grant/Research Support recipient: Adare/Ellodi, Allakos, AstraZeneca, Banner, Celgene/Receptos/Bristol Myers Squibb, GlaxoSmithKline, Holoclara, Meritage, Miraca, Nutricia, Regeneron, Shire/Takeda

Raquel Durban, MS, RD, CSP, LDN
Nothing to disclose

Gary W. Falk, MD, MS
Consultant (Occasional): Allakos, Bristol Myers Squibb, CDX, Cernostics, Ellodi, Ellodi, Lucid, Phathom, Regeneron, Takeda
Grant/Research Support recipient: Allakos, Arena, Bristol Myers Squibb, Interpace, Lucid, Regeneron, Shire/Takeda

Calies Menard-Katcher, MD, MSCS
Nothing to disclose

Robert Pesek, MD
Nothing to disclose

Conflict of Interest Policy/Disclosure Statement

The content for this activity was developed independently of the commercial supporter. All materials are included with permission. The opinions expressed are those of the faculty and are not to be construed as those of the publisher or grantor.

This educational activity was planned and produced in accordance with the ACCME Accreditation Criteria, Policies, and Standards for Commercial Support. Recommendations involving clinical medicine in a continuing medical education (CME) activity must be based on evidence that is accepted within the profession of medicine as adequate justification for their indications and contraindications in the care of patients. All scientific research referred to, reported, or used in CME in support or justification of a patient care recommendation must conform to the generally accepted standards of experimental design, data collection, and analysis.

This CME activity might describe the off-label, investigational, or experimental use of medications and/or devices that may exceed their FDA-approved labeling. Physicians should consult the current manufacturers’ prescribing information for these products. ACHL requires the speaker to disclose that a product is not labeled for the use under discussion.

Accreditation Statement

The Academy for Continued Healthcare Learning is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Designation of Credit

The Academy for Continued Healthcare Learning designates this enduring material for a maximum of 2.0 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Instructions for Receiving Credit

This activity will take approximately 120 minutes to complete. To receive credit, participants are required to complete the pretest, view the online activity, and complete the posttest and evaluation. To receive credit, 66% must be achieved on the posttest. A certificate will be immediately available. There is no fee to participate in the activity or for the generation of the certificate.

Statement of Commercial Support

Supported by an educational grant from Takeda Pharmaceuticals U.S.A., Inc.

Disclaimer Statement/Disclosure of Unlabeled Use

Discussion of Off-Label, Investigational, or Experimental Drug/Device Use: Topical steroids and biologic agents under investigation for EoE

Contact Information for Questions About the Activity

For questions, contact Laurie Novoryta at Lnovoryta@achlcme.org.

Activity Details

Free CME
2.0 AMA PRA Category 1 Credit(s)
Released: June 4, 2021
Expires: June 4, 2022
120 minutes to complete

Accredited By

Target Audience

This activity is intended for gastroenterologists, allergists, primary care physicians, pediatricians, advanced practice providers, and nurses who care for patients with swallowing disorder.

Learning Objectives

Upon completion of this activity, participants will be able to:

  • Identify patients with EoE using the latest diagnostic recommendations and criteria
  • Outline the reasoning for why EoE must be viewed as a chronic rather than an acute disease
  • Incorporate strategies to facilitate coordinated interdisciplinary EoE care among gastroenterologists, allergists, and nutritionists
  • Evaluate the latest safety and efficacy data with the therapies in clinical trials for EoE
  • Indicate the potential roles of investigational treatments in EoE management plans

Activity Description

Did you know that the incidence of eosinophilic esophagitis (EoE) is increasing rapidly? Are you familiar with the burdens faced by adult and pediatric patients living with EoE? In this multi-module activity led by an interdisciplinary panel, access practical guidance and supplemental resources on the management and treatment of EoE. Navigate at your own pace through video modules and an interactive infographic with animated content and expert commentary.

Faculty discussion will focus on:

  • Recognizing and diagnosing EoE
  • Treating EoE as a chronic disease
  • Novel developments in treatment

Statement of Educational Need

EoE is an immune-mediated, chronic disease that has been steadily increasing in prevalence and incidence over the past 30 years. Clinicians need to understand that the natural history of the EoE consists of chronic inflammation that may progress into fibrous remodeling. Problematically, EoE diagnosis can be challenging for clinicians, and is often considered the last diagnosis. Thus, clinicians need to be more aware of EoE to decrease diagnostic delays. This activity will also raise awareness that EoE is a chronic disease that requires extended therapy and educate clinicians on emerging therapeutic options and the newest guidelines. Finally, clinicians need to improve their multidisciplinary management of EoE to improve outcomes.

Agenda

Video Module - Introduction to EoE and Its Diagnosis
Video Module - EoE: A Chronic Disease With Unmet Treatment Needs
Video Module - It Takes a Village: Interdisciplinary Care for EoE
Interactive Infographic - Practical Points for the Diagnosis and Chronic Treatment of EoE

Faculty

Evan Dellon, MD, MPH
Department of Medicine
Division of Gastroenterology and Hepatology
Adjunct Professor of Epidemiology
Director, CGIBD Biostatistics and Clinical Research Core
Director, Center for Esophageal Diseases and Swallowing
School of Medicine, University of North Carolina at Chapel Hill
Chapel Hill, NC

Raquel Durban, MS, RD, CSP, LDN
Carolina Asthma & Allergy Center
Registered Dietitian
Charlotte, NC

Gary W. Falk, MD, MS
Professor of Medicine
Division of Gastroenterology
University of Pennsylvania Perelman School of Medicine
Philadelphia, PA

Calies Menard-Katcher, MD, MSCS
Associate Professor of Pediatrics
Associate Director of Clinical Research for the GEDP
Division of Gastroenterology Hepatology and Nutrition
Department of Pediatrics
University of Colorado School of Medicine
Gastrointestinal Eosinophilic Diseases Program
Digestive Health Institute
Children's Hospital Colorado
Aurora, CO

Robert Pesek, MD
Medical Director, Asthma
Medical Director, Eosinophilic Gastrointestinal Disorders Clinic
Associate Professor of Pediatrics and Allergy/Immunology
Arkansas Children's Hospital and the University of Arkansas for Medical Sciences
Little Rock, AR

The Academy for Continued Healthcare Learning (ACHL) requires that the faculty participating in an accredited continuing education activity disclose all affiliations or other financial relationships (1) with the manufacturers of any commercial product(s) and/or provider(s) of commercial services discussed in an educational presentation and (2) with any commercial supporters of the activity. All conflicts of interest have been mitigated prior to this activity.

The following financial relationships have been provided:

Evan Dellon, MD, MPH
Consultant (Occasional): Abbott, Adare/Ellodi, Aimmune, Allakos, Amgen, Arena, AstraZeneca, Avir, Biorasi, Calypso, Celgene/Receptos/Bristol Myers Squibb, Celldex, Eli Lilly, EsoCap, GlaxoSmithKline, Gossamer Bio, Parexel, Regeneron, Robarts/Alimentiv, Salix, Sanofi, Shire/Takeda
Grant/Research Support recipient: Adare/Ellodi, Allakos, AstraZeneca, Banner, Celgene/Receptos/Bristol Myers Squibb, GlaxoSmithKline, Holoclara, Meritage, Miraca, Nutricia, Regeneron, Shire/Takeda

Raquel Durban, MS, RD, CSP, LDN
Nothing to disclose

Gary W. Falk, MD, MS
Consultant (Occasional): Allakos, Bristol Myers Squibb, CDX, Cernostics, Ellodi, Ellodi, Lucid, Phathom, Regeneron, Takeda
Grant/Research Support recipient: Allakos, Arena, Bristol Myers Squibb, Interpace, Lucid, Regeneron, Shire/Takeda

Calies Menard-Katcher, MD, MSCS
Nothing to disclose

Robert Pesek, MD
Nothing to disclose

Conflict of Interest Policy/Disclosure Statement

The content for this activity was developed independently of the commercial supporter. All materials are included with permission. The opinions expressed are those of the faculty and are not to be construed as those of the publisher or grantor.

This educational activity was planned and produced in accordance with the ACCME Accreditation Criteria, Policies, and Standards for Commercial Support. Recommendations involving clinical medicine in a continuing medical education (CME) activity must be based on evidence that is accepted within the profession of medicine as adequate justification for their indications and contraindications in the care of patients. All scientific research referred to, reported, or used in CME in support or justification of a patient care recommendation must conform to the generally accepted standards of experimental design, data collection, and analysis.

This CME activity might describe the off-label, investigational, or experimental use of medications and/or devices that may exceed their FDA-approved labeling. Physicians should consult the current manufacturers’ prescribing information for these products. ACHL requires the speaker to disclose that a product is not labeled for the use under discussion.

Accreditation Statement

The Academy for Continued Healthcare Learning is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Designation of Credit

The Academy for Continued Healthcare Learning designates this enduring material for a maximum of 2.0 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Instructions for Receiving Credit

This activity will take approximately 120 minutes to complete. To receive credit, participants are required to complete the pretest, view the online activity, and complete the posttest and evaluation. To receive credit, 66% must be achieved on the posttest. A certificate will be immediately available. There is no fee to participate in the activity or for the generation of the certificate.

Statement of Commercial Support

Supported by an educational grant from Takeda Pharmaceuticals U.S.A., Inc.

Disclaimer Statement/Disclosure of Unlabeled Use

Discussion of Off-Label, Investigational, or Experimental Drug/Device Use: Topical steroids and biologic agents under investigation for EoE

Contact Information for Questions About the Activity

For questions, contact Laurie Novoryta at Lnovoryta@achlcme.org.

1.00 CME / MOC
Forefront Collaborative
Systemic Lupus Erythematosus: Patient-Centered Care to Improve Disease Control—Share, Learn, Engage: Novel Targeted Therapies in the Treatment of Systemic Lupus Erythematosus

Systemic Lupus Erythematosus: Patient-Centered Care to Improve Disease Control—Share, Learn, Engage: Novel Targeted Therapies in the Treatment of Systemic Lupus Erythematosus

Start

Activity Details

Free CME/ABIM MOC
1.0 AMA PRA Category 1 Credit(s)
1.0 ABIM MOC Part II Points
Released: May 21, 2021
Expires: May 21, 2022
60 minutes to complete

Accredited By

Target Audience

The primary target audience for this activity is rheumatologists who practice in the United States (US) and outside the US. Other rheumatology providers and other clinicians who treat patients with systemic lupus erythematosus (SLE) can benefit from participation.

Learning Objectives

As a result of participation in this educational activity, participants should be able to:

  • Discuss immunopathogenesis of SLE in relation to novel targeted therapies.
  • Translate available and emerging clinical trial data and outcomes into clinically meaningful information for providing care to patients with SLE.
  • Explain data about treatment options to patient with SLE.

Activity Description

Immerse yourself in this 60-minute interactive activity to meet a patient with systemic lupus erythematosus (SLE), view concise presentations, and engage in hands-on experience with the content. This activity will highlight the immunopathogenesis of SLE and mechanisms of action of therapies. Additionally, leading clinical experts will review clinical trial data and outcomes, both available and emerging, and translate them into clinically meaningful information for patient care. This activity is one of two in the series, Systemic Lupus Erythematosus: Patient-Centered Care to Improve Disease Control.

For the best experience, use a laptop, desktop, or tablet with the Google Chrome browser.

Faculty

Sheetal Desai, MD, MSEd
Chief of Rheumatology,
Rheumatology Fellowship Program Director,
Director, Lupus Clinic
Associate Clinical Professor of Medicine,
Division of Rheumatology
University of California, Irvine
Irvine, California


Bevra H. Hahn, MD
Distinguished Professor of Medicine (Emeritus),
Division of Rheumatology
University of California, Los Angeles
Los Angeles, California


Lauren Irving
Patient Presenter

Conflict of Interest Policy/Disclosure Statement

Educational activities provided by Forefront Collaborative must demonstrate balance, independence, and scientific rigor. All those in a position to control the content of an activity must disclose all relevant financial relationship(s) with commercial interest(s)*. For this educational activity, all conflicts of interest have been resolved through peer review and revisions to ensure independence, evidence base, fair balance, and absence of commercial bias. Disclosures appear below.

*The ACCME defines a commercial interest as any entity producing, marketing, reselling, or distributing health care goods or services consumed by or used on patients. The ACCME does not consider providers of clinical service directly to patients to be commercial interests – unless the provider of clinical service is owned, or controlled by, an ACCME-defined commercial interest.

The following individuals have indicated that neither they nor their spouses/partners have had, in the past 12 months, financial relationship(s) with commercial interests relative to the content of this CME activity:

  • Planners (Forefront Collaborative): Marianna Shershneva, MD, PhD, and Megan Ragan
  • Presenter: Lauren Irving

The following individuals have disclosed that they and/or their spouse/partner has had a financial relationship in the past 12 months:

Presenter: Sheetal Desai, MD, MSEd

  • Advisory Board: Janssen, GlaxoSmithKline
  • Speakers Bureau: Janssen, GlaxoSmithKline

Presenter: Bevra H. Hahn, MD

  • Advisory Board: Janssen
  • Consulting Fee: Aurinia
  • Data Safety Monitoring: UCB

CME Content Review

The views and opinions expressed in this activity are those of the faculty and do not necessarily reflect the views or recommendations of Forefront Collaborative and Lilly.

The content of this activity was independently peer reviewed by two reviewers. The reviewers of this activity have no relevant financial relationships to disclose.

This continuing medical education activity will include reference(s) to unlabeled or unapproved uses of drugs.

Accreditation Statement

Forefront Collaborative is accredited with commendation by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Designation of Credit

ACCME: Forefront Collaborative designates this enduring activity for a maximum of 1.0 AMA PRA Category 1 Credit(s)™; physicians should claim only the creditcommensurate with the extent of their participation in the activity.

ABIM MOC: Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 1.0 Medical Knowledge MOC points in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

UEMS-EACCME®: The UEMS-EACCME® has an agreement of mutual recognition of AMA PRA Category 1 Credit(s)™. International physicians interested in converting AMA PRA Category 1 Credit(s)™ to EACCME credit should contact the UEMS, https://www.uems.eu/.

Statement of Commercial Support

This activity is supported by an educational grant from Lilly. For further information concerning Lilly grant funding, visit www.lillygrantoffice.com.

Activity Details

Free CME/ABIM MOC
1.0 AMA PRA Category 1 Credit(s)
1.0 ABIM MOC Part II Points
Released: May 21, 2021
Expires: May 21, 2022
60 minutes to complete

Accredited By

Target Audience

The primary target audience for this activity is rheumatologists who practice in the United States (US) and outside the US. Other rheumatology providers and other clinicians who treat patients with systemic lupus erythematosus (SLE) can benefit from participation.

Learning Objectives

As a result of participation in this educational activity, participants should be able to:

  • Discuss immunopathogenesis of SLE in relation to novel targeted therapies.
  • Translate available and emerging clinical trial data and outcomes into clinically meaningful information for providing care to patients with SLE.
  • Explain data about treatment options to patient with SLE.

Activity Description

Immerse yourself in this 60-minute interactive activity to meet a patient with systemic lupus erythematosus (SLE), view concise presentations, and engage in hands-on experience with the content. This activity will highlight the immunopathogenesis of SLE and mechanisms of action of therapies. Additionally, leading clinical experts will review clinical trial data and outcomes, both available and emerging, and translate them into clinically meaningful information for patient care. This activity is one of two in the series, Systemic Lupus Erythematosus: Patient-Centered Care to Improve Disease Control.

For the best experience, use a laptop, desktop, or tablet with the Google Chrome browser.

Faculty

Sheetal Desai, MD, MSEd
Chief of Rheumatology,
Rheumatology Fellowship Program Director,
Director, Lupus Clinic
Associate Clinical Professor of Medicine,
Division of Rheumatology
University of California, Irvine
Irvine, California


Bevra H. Hahn, MD
Distinguished Professor of Medicine (Emeritus),
Division of Rheumatology
University of California, Los Angeles
Los Angeles, California


Lauren Irving
Patient Presenter

Conflict of Interest Policy/Disclosure Statement

Educational activities provided by Forefront Collaborative must demonstrate balance, independence, and scientific rigor. All those in a position to control the content of an activity must disclose all relevant financial relationship(s) with commercial interest(s)*. For this educational activity, all conflicts of interest have been resolved through peer review and revisions to ensure independence, evidence base, fair balance, and absence of commercial bias. Disclosures appear below.

*The ACCME defines a commercial interest as any entity producing, marketing, reselling, or distributing health care goods or services consumed by or used on patients. The ACCME does not consider providers of clinical service directly to patients to be commercial interests – unless the provider of clinical service is owned, or controlled by, an ACCME-defined commercial interest.

The following individuals have indicated that neither they nor their spouses/partners have had, in the past 12 months, financial relationship(s) with commercial interests relative to the content of this CME activity:

  • Planners (Forefront Collaborative): Marianna Shershneva, MD, PhD, and Megan Ragan
  • Presenter: Lauren Irving

The following individuals have disclosed that they and/or their spouse/partner has had a financial relationship in the past 12 months:

Presenter: Sheetal Desai, MD, MSEd

  • Advisory Board: Janssen, GlaxoSmithKline
  • Speakers Bureau: Janssen, GlaxoSmithKline

Presenter: Bevra H. Hahn, MD

  • Advisory Board: Janssen
  • Consulting Fee: Aurinia
  • Data Safety Monitoring: UCB

CME Content Review

The views and opinions expressed in this activity are those of the faculty and do not necessarily reflect the views or recommendations of Forefront Collaborative and Lilly.

The content of this activity was independently peer reviewed by two reviewers. The reviewers of this activity have no relevant financial relationships to disclose.

This continuing medical education activity will include reference(s) to unlabeled or unapproved uses of drugs.

Accreditation Statement

Forefront Collaborative is accredited with commendation by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Designation of Credit

ACCME: Forefront Collaborative designates this enduring activity for a maximum of 1.0 AMA PRA Category 1 Credit(s)™; physicians should claim only the creditcommensurate with the extent of their participation in the activity.

ABIM MOC: Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 1.0 Medical Knowledge MOC points in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

UEMS-EACCME®: The UEMS-EACCME® has an agreement of mutual recognition of AMA PRA Category 1 Credit(s)™. International physicians interested in converting AMA PRA Category 1 Credit(s)™ to EACCME credit should contact the UEMS, https://www.uems.eu/.

Statement of Commercial Support

This activity is supported by an educational grant from Lilly. For further information concerning Lilly grant funding, visit www.lillygrantoffice.com.

1.00 CME
SHM (Society of Hospital Medicine)
Hospitalists Guide to COVID-19

Hospitalists Guide to COVID-19

Start

Activity Details

Free CME
1.0 AMA PRA Category 1 Credit(s)
Released: May 4, 2021
Expires: May 3, 2022
60 minutes to complete

Accredited By

Target Audience

Hospitalists (all hospital clinicians treating patients with COVID-19)

Learning Objectives

  1. Discuss the findings from randomized clinical trials for treatments for hospitalized patients
  2. Evaluate current guidance for treatment of patients requiring hospitalization

Activity Description

Webinar featuring a panelist of hospitalists and infectious disease experts review up-to-date information on clinical staging, progression, and current management of COVID-19, including updates on coagulopathy.

Agenda

  • Hospital Medicine: COVID-19 Treatment and Clinical Care
  • Clinical Management & Coagulopathy Updates
  • COVID-19 Therapeutics for Hospitalized Patients

Course Director

Ebrahim Barkoudah, MD, MPH, FACP, SFHM
Associate Director of Hospital Medicine Unit
Medical Director of Department of Medicine
Brigham and Women's Hospital
Assistant Professor of Medicine
Harvard Medical School
Boston, MA

Research support payments from National Institutes of Health/National Heart, Lung, and Blood Institute; Bristol Myers Squibb; and Janssen. Payments made to Brigham and Women's Hospital for performing clinical endpoints sponsored by various entities. Advisory Board fees from Bristol Myers Squibb, Janssen, Novartis, Pfizer, and Portola/Alexion.

Expert Speakers

William Garneau, MD, MPH
Assistant Professor of Medicine
Division of Hospital Medicine
Johns Hopkins Hospital
Baltimore, MD

Stock: J&J, AstraZeneca.

Paul G. Auwaerter, MD, MBA, FIDSA
Clinical Director
Division of Infectious Diseases
Johns Hopkins Hospital
Past President of the Infectious Diseases Society of America (IDSA)
Professor of Medicine
Johns Hopkins University School of Medicine
Baltimore, MD

Ownership equity: JNJ. Scientific Consulting: Verily, EMD Serono. DMSB: Humanigen.

Moderators

Ramesh Adhikari, MD, MS, SFHM
Hospitalist/Geriatrician
Society of Hospital Medicine (SHM) Indiana Chapter
President
Franciscan Health Lafayette East Hospital
Lafayette, IN

Jose Mercado, MD, MPH
Hospital Epidemiologist
Dartmouth-Hitchcock
Assistant Professor of Medicine
Geisel School of Medicine
Medical Director
Alice Peck Day Hospital
Lebanon, NH

Conflict of Interest Policy/Disclosure Statement

All activity, content, and materials have been developed solely by the activity directors, planning committee members, and faculty presenters, and are free of influence from a commercial entity.

Accreditation Statement

The Society of Hospital Medicine designates this enduring activity for a maximum of 1.0 AMA PRA Category 1 Credit(s)™. Physicians should only claim credit commensurate with the extent of their participation in this activity. This activity is classified as non-variable credit. The entire module must be completed to receive credit.

The Society of Hospital Medicine is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

SHM is dedicated to promoting the highest quality care for all hospitalized patients. SHM is committed to promoting excellence in the practice of hospital medicine through education, advocacy, and research.

Statement of Commercial Support

This activity was made possible in part by an educational grant from Gilead Sciences, Inc.

Disclaimer Statement/Disclosure of Unlabeled Use

The presenters have indicated that they will be referencing the unlabeled or unapproved use of agents currently being investigated in ongoing studies, including tocilizumab, dexamethasone, and COVID-19 convalescent plasma.

Activity Details

Free CME
1.0 AMA PRA Category 1 Credit(s)
Released: May 4, 2021
Expires: May 3, 2022
60 minutes to complete

Accredited By

Target Audience

Hospitalists (all hospital clinicians treating patients with COVID-19)

Learning Objectives

  1. Discuss the findings from randomized clinical trials for treatments for hospitalized patients
  2. Evaluate current guidance for treatment of patients requiring hospitalization

Activity Description

Webinar featuring a panelist of hospitalists and infectious disease experts review up-to-date information on clinical staging, progression, and current management of COVID-19, including updates on coagulopathy.

Agenda

  • Hospital Medicine: COVID-19 Treatment and Clinical Care
  • Clinical Management & Coagulopathy Updates
  • COVID-19 Therapeutics for Hospitalized Patients

Course Director

Ebrahim Barkoudah, MD, MPH, FACP, SFHM
Associate Director of Hospital Medicine Unit
Medical Director of Department of Medicine
Brigham and Women's Hospital
Assistant Professor of Medicine
Harvard Medical School
Boston, MA

Research support payments from National Institutes of Health/National Heart, Lung, and Blood Institute; Bristol Myers Squibb; and Janssen. Payments made to Brigham and Women's Hospital for performing clinical endpoints sponsored by various entities. Advisory Board fees from Bristol Myers Squibb, Janssen, Novartis, Pfizer, and Portola/Alexion.

Expert Speakers

William Garneau, MD, MPH
Assistant Professor of Medicine
Division of Hospital Medicine
Johns Hopkins Hospital
Baltimore, MD

Stock: J&J, AstraZeneca.

Paul G. Auwaerter, MD, MBA, FIDSA
Clinical Director
Division of Infectious Diseases
Johns Hopkins Hospital
Past President of the Infectious Diseases Society of America (IDSA)
Professor of Medicine
Johns Hopkins University School of Medicine
Baltimore, MD

Ownership equity: JNJ. Scientific Consulting: Verily, EMD Serono. DMSB: Humanigen.

Moderators

Ramesh Adhikari, MD, MS, SFHM
Hospitalist/Geriatrician
Society of Hospital Medicine (SHM) Indiana Chapter
President
Franciscan Health Lafayette East Hospital
Lafayette, IN

Jose Mercado, MD, MPH
Hospital Epidemiologist
Dartmouth-Hitchcock
Assistant Professor of Medicine
Geisel School of Medicine
Medical Director
Alice Peck Day Hospital
Lebanon, NH

Conflict of Interest Policy/Disclosure Statement

All activity, content, and materials have been developed solely by the activity directors, planning committee members, and faculty presenters, and are free of influence from a commercial entity.

Accreditation Statement

The Society of Hospital Medicine designates this enduring activity for a maximum of 1.0 AMA PRA Category 1 Credit(s)™. Physicians should only claim credit commensurate with the extent of their participation in this activity. This activity is classified as non-variable credit. The entire module must be completed to receive credit.

The Society of Hospital Medicine is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

SHM is dedicated to promoting the highest quality care for all hospitalized patients. SHM is committed to promoting excellence in the practice of hospital medicine through education, advocacy, and research.

Statement of Commercial Support

This activity was made possible in part by an educational grant from Gilead Sciences, Inc.

Disclaimer Statement/Disclosure of Unlabeled Use

The presenters have indicated that they will be referencing the unlabeled or unapproved use of agents currently being investigated in ongoing studies, including tocilizumab, dexamethasone, and COVID-19 convalescent plasma.

Pages